You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Express Scripts

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,251,873

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,251,873 protect, and when does it expire?

Patent 10,251,873 protects GALAFOLD and is included in one NDA.

This patent has forty-seven patent family members in twenty-two countries.

Summary for Patent: 10,251,873
Title:Methods of treating fabry patients having renal impairment
Abstract: Provided are methods for treatment of Fabry disease in a patient having renal impairment and/or elevated proteinuria. Certain methods comprise administering to the patient about 100 to about 150 mg free base equivalent of migalastat or salt thereof at a frequency of once every other day. Certain methods also provide for the stabilization of renal function, reducing left ventricular mass index, reducing plasma globotriaosylsphingosine and/or increasing .alpha.-galactosidase A activity in the patient.
Inventor(s): Castelli; Jeff (New Hope, PA), Benjamin; Elfrida (Millstone Township, NA)
Assignee: Amicus Therapeutics, Inc. (Cranbury, NJ)
Application Number:15/992,336
Patent Claim Types:
see list of patent claims
Use; Delivery; Dosage form;

Drugs Protected by US Patent 10,251,873

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Amicus Theraps Us GALAFOLD migalastat hydrochloride CAPSULE;ORAL 208623-001 Aug 10, 2018 RX Yes Yes   Start Trial   Start Trial THE TREATMENT OF FABRY PATIENTS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.